Compare GTX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTX | CORT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Switzerland | United States |
| Employees | N/A | 500 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | GTX | CORT |
|---|---|---|
| Price | $18.38 | $35.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $20.00 | ★ $111.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.9M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 55.30 | N/A |
| EPS | ★ 1.57 | 0.87 |
| Revenue | ★ $3,537,000,000.00 | $741,172,000.00 |
| Revenue This Year | $3.71 | $21.70 |
| Revenue Next Year | $3.11 | $30.13 |
| P/E Ratio | ★ $12.22 | $40.52 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $7.02 | $32.99 |
| 52 Week High | $19.27 | $117.33 |
| Indicator | GTX | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 20.88 |
| Support Level | $18.52 | $34.28 |
| Resistance Level | $19.09 | $37.48 |
| Average True Range (ATR) | 0.51 | 2.91 |
| MACD | 0.07 | -1.12 |
| Stochastic Oscillator | 65.15 | 4.22 |
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.